Valneva (NASDAQ:VALN) Stock Price Down 5.6% – What’s Next?

Valneva SE Sponsored ADR (NASDAQ:VALN) shares were down 5.6% during mid-day trading on Monday . The stock traded as low as $9.25 and last traded at $9.2210. Approximately 5,954 shares were traded during trading, a decline of 59% from the average daily volume of 14,395 shares. The stock had previously closed at $9.77.

Analysts Set New Price Targets

A number of brokerages have recently commented on VALN. Weiss Ratings reissued a “sell (d-)” rating on shares of Valneva in a research note on Wednesday, October 8th. Wall Street Zen lowered Valneva from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Valneva has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Valneva Stock Performance

The company has a market capitalization of $784.46 million, a price-to-earnings ratio of -6.33 and a beta of 1.83. The company has a current ratio of 1.78, a quick ratio of 1.36 and a debt-to-equity ratio of 0.72. The stock has a 50-day simple moving average of $9.06 and a 200-day simple moving average of $9.15.

Valneva (NASDAQ:VALN) last issued its earnings results on Thursday, November 20th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.31). The company had revenue of $34.01 million during the quarter, compared to analyst estimates of $48.85 million. Valneva had a negative net margin of 57.81% and a negative return on equity of 59.44%. On average, analysts anticipate that Valneva SE Sponsored ADR will post 0.13 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of VALN. VSM Wealth Advisory LLC raised its position in Valneva by 125.0% in the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock worth $110,000 after acquiring an additional 5,000 shares in the last quarter. JPMorgan Chase & Co. purchased a new position in Valneva during the 3rd quarter worth approximately $124,000. Marex Group plc acquired a new stake in Valneva during the 2nd quarter valued at $64,000. Finally, Frazier Life Sciences Management L.P. purchased a new stake in shares of Valneva in the second quarter valued at $8,240,000. 11.39% of the stock is owned by institutional investors and hedge funds.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.